Rapid Diagnostic Systems Announces CE Mark Approval for NaorCov-19 Rapid Molecular Diagnosis of COVID-19
March 25, 2021
Rapid Diagnostic Systems Limited (RDS), www.narodia.com, an Israeli startup developing diagnostic solutions announced today that the company’s NaorCov-19, which enables rapid and scalable saliva based COVID-19 molecular diagnosis, has received the CE-European Conformity Mark approval.
The CE marking confirms that NaorCov-19 meets the requirements of the European Medical Devices Directive, which will allow RDS to commercialize the device across the European Union and other CE Mark geographies.
The patented NaorCov-19 device uses a unique saliva collection and processing device, coupled with a rapid molecular diagnostic process that could be conducted with affordable heating devices. It can be used to process locally and rapidly hundreds of samples within less than an hour, using affordable devices and without a need for highly skilled personnel. The testing procedure is easy to operate, with immediate high accuracy results for symptomatic and asymptomatic patients.
RDS is a company is developing and building its platform based on core molecular diagnostic technologies developed by a multidisciplinary research team from the Israeli Technion’s Schools of Medicine and Mechanical Engineering. The NaorCov-19 had been tested in a variety of clinical settings at leading medical institutions worldwide. The company is collaborating with MAFAT, the Israeli R&D arm of the Israeli Ministry of Defense.